Top-News
Biotechnologie Australien

Mesoblast Ltd ADR News

Aktie
WKN:  A4004R ISIN:  US5907174016 US-Symbol:  MESO
7,50 $
+0,20 $
+2,74%
03.05.24 21:56:31
Handeln Depot/Watchlist
Aktienanzahl *
101,48 Mio.
Marktkapitalisierung *
682,18 Mio. €
Streubesitz
-
Faktor
0.2
Originalaktie
AU000000MSB8
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 13.03.2024

Mesoblast Ltd ADR News

19.01.24 - PR Newswire
Thinking about buying stock in Coffee Holding Co., Aquestive Therapeutics, Snowflake Inc, Mesoblast, or Modular Medical?
Thinking about buying stock in Coffee Holding Co., Aquestive Therapeutics, Snowflake Inc, Mesoblast, or Modular Medical? PR Newswire
21.12.23 - PR Newswire
Thinking about buying stock in Hookipa Pharma, Riot Platforms, Celestica, Mesoblast, or MeiraGTx?
Thinking about buying stock in Hookipa Pharma, Riot Platforms, Celestica, Mesoblast, or MeiraGTx? PR Newswire
18.08.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO PR Newswire
10.08.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO PR Newswire
04.08.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO PR Newswire
24.07.12 - PR Newswire
Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis PR Newswire

Newssuche

Videos

03.05.24 0,00%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »